Management of chronic hepatitis B infection: Current treatment guidelines, challenges, and new developments

doi:10.3748/wjg.v20.i20.6262

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 20

This Article

(381)

(388)

(0)

(18049)

(114)

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Topic Highlight

World J Gastroenterol. May 28, 2014; 20(20): 6262-6278
Published online May 28, 2014. doi: 10.3748/wjg.v20.i20.6262

Table 8 Emerging pipeline drugs for chronic hepatitis B virus infection

Drug name	Mechanism of action	Status
Nucleos(t)ide analogues
Clevudine	Inhibits DNA polymerase	Partial approval
Emtricitabine	Inhibits DNA polymerase	FDA approved for HIV
Nucleos(t)ide analogue prodrugs
Amdoxovir	Inhibits DNA polymerase	II (for HIV)
LB80380	Inhibits DNA polymerase	IIb
Famciclovir	Inhibits DNA polymerase	Abandoned
Pradefovir	Inhibits DNA polymerase	Abandoned
Tenofovir alafenamide (GS 7340)	Inhibits DNA polymerase	II/III
MIV-210	Inhibits DNA polymerase	Abandoned
Non-nucleos(t)ide antivirals
NOV-205 (BAM 205)	Unknown	Approved in Russia
Myrcludex-B	Inhibits viral entry	Ib/IIa
Bay 41-4109	Inhibits viral core formation	I
GLS4	Inhibits HBV viral core assembly	Pre-clinical
Rep 9 AC	Blocks HBsAg release	II
NVR-1221	Capsid inhibitor	Pre-clinical
Immunomodulators
Pegylated interferon lambda	Cytokine modulating innate/adaptive immune response	I
GS-9620	TLR-7 agonist	Pre-clinical
Nitazoxanide	Unknown	II
EHT899	Immune enhancer	II
Therapeutic vaccines
HBV core antigen vaccine	Enhance T cell response	I
HBV-EPV	Immunogenic	Withdrawn
ePA-44	Immunogenic	II
HI-8 HBV	Stimulates IFN-γ producing T cells	II
Others
β-thujaplicinol	Blocks viral ribonuclease H activity	Pre-clinical
ARC520	RNA interference	I
Herbal bushen formula	Down-regulate CD4⁺ and CD25⁺ T cells	TCM

HBV: Hepatitis B virus; TCM: Traditional chinese medicine; HBsAg: Hepatitis B surface antigen; HIV: Human immunodeficiency virus; FDA: Food and Drug Administration; IFN: Interferon.

Full Size Table

Citation: Tang CM, Yau TO, Yu J. Management of chronic hepatitis B infection: Current treatment guidelines, challenges, and new developments. World J Gastroenterol 2014; 20(20): 6262-6278
URL: https://www.wjgnet.com/1007-9327/full/v20/i20/6262.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i20.6262

Tang CM, Yau TO, Yu J. Management of chronic hepatitis B infection: Current treatment guidelines, challenges, and new developments. World J Gastroenterol 2014; 20(20): 6262-6278 [PMID: 24876747 DOI: 10.3748/wjg.v20.i20.6262]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.